HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and nrtis emtricitabine and tenofovir in vitro

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 4, 2013, Pages 367-374

  Andreatta, Kristen ^a   Miller, Michael D ^a   White, Kirsten L ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Elvitegravir; Emtricitabine; HIV 2; Resistance; Tenofovir

Indexed keywords

ARGININE; ASPARAGINE; ELVITEGRAVIR; EMTRICITABINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; INTEGRASE; ISOLEUCINE; LYSINE; METHIONINE; PHENYLALANINE; SERINE; TENOFOVIR; TYROSINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS STRAIN;

EID: 85027938452     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827b55f1     Document Type: Article

References (47)

1. Sharp PM, Bailes E, Chaudhuri RR, et al. The origins of acquired immune deficiency syndrome viruses: where and when? Philos Trans R Soc Lond B Biol Sci. 2001;356:867-876.
2. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends Microbiol. 2008;16:588-595.
3. Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis. 2011;52:780-787.
4. Ntemgwa ML, d'Aquin Toni T, Brenner BG, et al. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother. 2009;53:3611-3619.
5. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57-65.
6. Charpentier C, Roquebert B, Delelis O, et al. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother. 2011;55:1293-1295.
7. Ni XJ, Delelis O, Charpentier C, et al. G140S/Q148R and N155H mutations render HIV-2 integrase resistant to raltegravir whereas Y143C does not. Retrovirology. 2011;8:68.
8. Smith RA, Raugi DN, Kiviat NB, et al. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance. AIDS. 2011;25:2235-2241.
9. Colson P, Henry M, Tivoli N, et al. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol. 2005;75:381-390.
10. Jallow S, Kaye S, Alabi A, et al. Virological and immunological response to combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in the Gambia. AIDS. 2006;20:1455-1458.
11. Smith RA, Anderson DJ, Pyrak CL, et al. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis. 2009;199:1323-1326.
12. Descamps D, Damond F, Matheron S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004;74:197-201.
13. McColl DJ, Chappey C, Parkin NT, et al. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir Ther. 2008;13:189-197.
14. Ruelle J, Roman F, Vandenbroucke AT, et al. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC Infect Dis. 2008;8:21.
15. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439-2448.
16. DeJesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429-2438.
17. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008;82:764-774.
18. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antivir Ther. 2001;6:83-88.
19. Balzarini J, Holý A, Jindrich J, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2, 6-diaminopurine. Antimicrob Agents Chemother. 1993;37:332-338.
20. Guyader M, Emerman M, Montagnier L, et al. VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J. 1989;8:1169-1175.
21. Margot NA, Hluhanich RM, Jones GS, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2012;93:288-296.
22. Bercoff DP, Triqueneaux P, Lambert C, et al. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology. 2010;7:98.
23. Gao F, Yue L, Robertson DL, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994;68:7433-7447.
24. Zagury JF, Franchini G, Reitz M, et al. Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. Proc Natl Acad Sci U S A. 1988;85: 5941-5945.
25. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62:914-920.
26. Ruelle J, Sanou M, Liu HF, et al. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso. AIDS Res Hum Retroviruses. 2007;23:955-964.
27. Smith RA, Gottlieb GS, Anderson DJ, et al. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother. 2008;52:329-332.
28. Margot NA, Rhee MS, Szwarcberg J, et al. Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-us-183-0145. Poster presented at: XIX International AIDS Conference; July 22-27, 2012; Washington, DC. Poster TUPE050.
29. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase 2 study of elvitegravir (GS-9137) [Abstract 9]. Paper presented at: 16th International HIV Drug Resistance Workshop; June 12-16, 2007; Bridgetown, Barbados.
30. Goodman DD, Hluhanich R, Waters JM, et al. Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increases resistance. Poster presented at: XVII International HIV Drug Resistance Workshop; June 10-14, 2008; Sitges, Spain. Poster 13.
31. Xu L, Anderson J, Garrett N, et al. Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses. 2009;25:843-847.
32. Smith RA, Raugi DN, Pan C, et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One. 2012;7:e45372.
33. Ntemgwa ML, Toni T, Brenner BG, et al. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother. 2009;53:708-715.
34. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother. 2006;50:4087-4095.
35. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-190.
36. Schinazi RF, Lloyd RM Jr, Nguyen MHH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37:875-881.
37. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-5656.
38. Kulkarni R, Babaoglu K, Lansdon EB, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr. 2012;59:47-54.
39. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999;4:87-94.
40. Margot NA, Isaacson E, McGowan I, et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002;16:1227-1235.
41. Margot NA, Lu B, Cheng A, et al. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in study 903. HIV Med. 2006;7:442-450.
42. Damond F, Matheron S, Peytavin G, et al. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. Antivir Ther. 2004;9:635-636.
43. Stone C, Ait-Khaled M, Craig C, et al. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother. 2004;48:1413-1415.
44. Wirden M, Marcelin AG, Simon A, et al. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients. J Med Virol. 2005;76:297-301.
45. Lanier ER, Givens N, Stone C, et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 2004;5:394-399.
46. Peterson K, Jallow S, Rowland-Jones SL, et al. Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings. AIDS Res Treat. 2011;2011:463704.
47. Peterson K, Ruelle J, Vekemans M, et al. The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. Antivir Ther. 2012;17:1097-1100.